ZIM to expand its refrigerated container fleet
The expansion of the refrigerated container fleet will support the growing demand for ZIMonitor, ZIM's premium reefer cargo tracking service.
ZIM Integrated Shipping Services has announced the expansion of its refrigerated container fleet to answer the demand for its innovative ZIMonitor service. Launched in early 2015, ZIMonitor allows customers to track, monitor and remotely control sensitive, high-value cargo stowed in refrigerated, or reefer, containers. Customers can opt to receive alerts regarding their shipment via text message or email, closely monitor their cargo's status and intervene to prevent damages through ZIM's 24/7 dedicated global response team.
An order of approximately 1,900x40-Feet High-Cube refrigerated containers is planned to be deployed during 2016. The new advanced and environmentally friendly containers were specifically designed to accommodate the ZIMonitor service and received a special prefix: ZMOU.
ZIM has partnered with Teva Pharmaceutical Industries, a leading global pharmaceutical company, on a successful pilot of the ZIMonitor service that addressed Teva's uncompromising commitment to the quality of its products and its dedication to meet the requirements of its customers. Upon the successful completion of the pilot, the ZIMonitor service quickly gained popularity among ZIM's customer base.
Nissim Yochai, ZIM's VP of Global Sales stated: "We are very pleased with the growing demand for our monitored services. The ZIMonitor system was designed by ZIM for the cold supply chain and employs state-of-the-art technology. The service provides a tailored solution for customers who ship pharmaceuticals, perishable food and other high-value and sensitive cargo. As part of ZIM's comprehensive strategy, we are committed to further enhance and improve our services in response to what the market needs."
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.